Search

Steve Glass brings more than three decades of experience across the healthcare provider and payer sectors and will oversee MSK’s financial strategy and operations.

… Thursday, March 19, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the appointment of Steve Glass as Executive Vice President and Chief Financial Officer effective immediately. Glass brings more than three decades of experience across the healthcare provider and payer sectors and will

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

… Tuesday, February 25, 2020 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited

ATLANTA, June 4, 2006 - According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

… Sunday, June 4, 2006 According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer , also known as metastatic renal cell carcinoma (mRCC). The study is being presented today

Lung cancer co-opts genes that normally help a fetus develop and evade the mother’s immune system — leading to poorer outcomes in female patients, an MSK research team has found.

… Monday, April 28, 2025 Lung cancer can co-opt genes that normally help a fetus develop and evade the mother’s immune system. And while these pregnancy-specific glycoproteins (PSGs) can get activated in the cancers of both men and women, female patients had poorer outcomes, a Memorial Sloan Kettering

In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and Jedd Wolchok MD, PhD, members of Memorial Sloan Kettering Cancer Center's Melanoma and Sarcoma service, and lead authors on the studies along with collaborators from more than a one hundred cancer centers worldwide.

… Sunday, June 5, 2011 In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.

… Wednesday, February 21, 2018 Bottom Line: Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical

Memorial Sloan Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.

… Thursday, October 2, 2008 Memorial Sloan Kettering Cancer Center (MSKCC) and Summit Medical Group (SMG) together announce a new collaborative relationship for the care of people with cancer. The initiative will give New Jersey residents who have cancer greater access to a broad array of services offered

MSK is helping young patients navigate their journey and get the best treatment through specialized counseling, digital connections, and more. “The gratitude I feel is so deep. I’m not just alive; I’m living,” says Desiree Allen.

… Friday, October 1, 2021 Before she was diagnosed with cancer in 2020 at age 31, Desiree Allen was living her best life. “I was in school part-time and working full-time, and I was — and still am — in a long-term relationship,” says the cardiology nurse, now 32. “As a matter of fact, I was having the

In this online discussion, panelists give tips for managing both your physical and mental well-being during the holiday season, especially against the backdrop of the ongoing pandemic.

… Tuesday, December 21, 2021 On Wednesday, December 15, 2021, a panel of Memorial Sloan Kettering Cancer Center (MSK) experts joined the Abyssinian Baptist Church in an online discussion that provided guidance and tips on staying mentally and physically healthy amid uncertainty, especially during this

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

… Wednesday, February 19, 2025 The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM ) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.  Sarcoma oncologist William Tap, MD , Chief of the